Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

ALGSAligos Therapeutics, Inc.

Nasdaq · CIK 0001799448
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts251

Identity from submissions API

NameAligos Therapeutics, Inc.
CIK0001799448
TickersALGS
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN000000000
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(800) 466-6059
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
CA
Mailing address
ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

350 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-005360 005-91770 261561464 34 11067
2026-11-13 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-007697 005-91770 261550664 34 21568
2026-11-06 10-Q 10-Q 0001193125-26-450798 001-39617 261529445 34 10361337 1 1
2026-11-06 8-K FORM 8-K 2.02,9.01 0001171843-26-007214 001-39617 261529412 34 263009 1 1
2026-09-15 8-K 8-K 1.01 0001193125-26-391880 001-39617 261380780 34 141244 1 1
2026-08-06 S-8 S-8 0001193125-26-337937 333-298052 261248801 33 218258 1 1
2026-08-06 10-Q 10-Q 0001193125-26-336851 001-39617 261246153 34 10162624 1 1
2026-08-06 8-K FORM 8-K 2.02,9.01 0001171843-26-005294 001-39617 261246101 34 269853 1 1
2026-06-29 4 xslF345X06/form4.xml 0001610717-26-000305 5446
2026-06-29 4 xslF345X06/form4.xml 0001610717-26-000304 5449
2026-06-29 4 xslF345X06/form4.xml 0001610717-26-000303 5436
2026-06-29 4 xslF345X06/form4.xml 0001610717-26-000302 5415
2026-06-29 4 xslF345X06/form4.xml 0001610717-26-000301 5456
2026-06-29 4 xslF345X06/form4.xml 0001610717-26-000300 5413
2026-06-26 8-K 8-K 5.02,5.07,9.01 0001193125-26-285426 001-39617 261128941 34 171496 1 1
2026-06-24 SCHEDULE 13D xslSCHEDULE_13D_X02/primary_doc.xml 0001193125-26-281134 005-91770 261116233 34 12943
2026-05-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-226938 005-91770 26988379 34 7177
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-003231 005-91770 26982817 34 9263
2026-05-07 10-Q 10-Q 0001193125-26-212001 001-39617 26953684 34 8168761 1 1
2026-05-07 8-K FORM 8-K 2.02,9.01 0001171843-26-003156 001-39617 26953211 34 256809 1 1
2026-04-29 DEFA14A DEFA14A 0001193125-26-191940 001-39617 26916887 34 542146
2026-04-29 ARS ARS 0001193125-26-191897 001-39617 26916682 34 1599365
2026-04-29 DEF 14A DEF 14A 0001193125-26-191843 001-39617 26916565 34 2759384 1 1
2026-04-21 8-K 8-K 1.01 0001193125-26-166987 001-39617 26879979 34 152686 1 1
2026-04-14 8-K 8-K 8.01,9.01 0001193125-26-154927 001-39617 26861021 34 169649 1 1
2026-03-11 4 xslF345X05/form4.xml 0001610717-26-000095 5506
2026-03-11 4 xslF345X05/form4.xml 0001610717-26-000094 5435
2026-03-11 4 xslF345X05/form4.xml 0001610717-26-000093 5482
2026-03-11 4 xslF345X05/form4.xml 0001610717-26-000092 5316
2026-03-05 S-8 S-8 0001193125-26-092647 333-294035 26724276 33 208350 1 1
2026-03-05 10-K 10-K 0001193125-26-092614 001-39617 26724251 34 14406492 1 1
2026-03-05 8-K FORM 8-K 2.02,9.01 0001171843-26-001340 001-39617 26724242 34 280714 1 1
2026-02-19 3 xslF345X02/form3.xml 0001610717-26-000055 15217
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-26-001065 005-91770 26640208 34 9009
2026-02-11 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-26-001502 005-91770 26621313 34 9536
2026-02-04 8-K 8-K 5.02 0001193125-26-037558 001-39617 26598187 34 137979 1 1
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-005026 005-91770 251486470 34 8996
2025-11-06 10-Q 10-Q 0001193125-25-268203 001-39617 251456393 34 9287937 1 1
2025-11-06 8-K FORM 8-K 2.02,9.01 0001171843-25-007075 001-39617 251456364 34 273843 1 1
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003590 005-91770 251216070 34 8785
2025-08-13 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-011951 005-91770 251210502 34 9401
2025-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003496 005-91770 251204311 34 13126
2025-08-06 S-8 S-8 0001193125-25-174519 333-289307 251190221 33 212280 1 1
2025-08-06 10-Q 10-Q 0000950170-25-104042 001-39617 251189726 34 9751079 1 1
2025-08-06 8-K FORM 8-K 2.02,9.01 0001171843-25-005116 001-39617 251189511 34 283307 1 1
2025-07-18 4 xslF345X05/form4.xml 0001610717-25-000290 5317
2025-07-18 4 xslF345X05/form4.xml 0001610717-25-000289 5507
2025-07-18 4 xslF345X05/form4.xml 0001610717-25-000286 5483
2025-06-26 4 xslF345X05/form4.xml 0001610717-25-000259 5300
2025-06-26 4 xslF345X05/form4.xml 0001610717-25-000258 5279
2025-06-26 4 xslF345X05/form4.xml 0001610717-25-000257 5277
2025-06-26 4 xslF345X05/form4.xml 0001610717-25-000256 5310
2025-06-26 4 xslF345X05/form4.xml 0001610717-25-000255 5313
2025-06-26 4 xslF345X05/form4.xml 0001610717-25-000254 5300
2025-06-26 8-K 8-K 5.02,5.03,5.07,9.01 0001193125-25-148905 001-39617 251080446 34 193499 1 1
2025-05-15 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-002361 005-91770 25953669 34 10426
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000935836-25-000358 005-91770 25951244 34 16739
2025-05-15 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-002357 005-91770 25949349 34 8670
2025-05-06 10-Q 10-Q 0000950170-25-063983 001-39617 25915358 34 8624265 1 1
2025-05-06 8-K FORM 8-K 2.02,9.01 0001171843-25-002781 001-39617 25915300 34 278896 1 1
2025-04-28 DEFA14A DEFA14A 0001193125-25-100542 001-39617 25880560 34 713938
2025-04-28 ARS ARS 0001193125-25-100516 001-39617 25880469 34 5863119
2025-04-28 DEF 14A DEF 14A 0001193125-25-100453 001-39617 25880257 34 2317178 1 1
2025-04-16 PRE 14A PRE 14A 0001193125-25-082777 001-39617 25842700 34 2325060 1 1
2025-04-03 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000975 333-286168 25811902 33 1772
2025-04-03 424B3 424B3 0001193125-25-072387 333-286168 25809839 33 226591
2025-04-01 CORRESP filename1.htm 0001193125-25-070406 7438
2025-04-01 UPLOAD filename1.pdf 0000000000-25-003496 333-286168 40172
2025-03-27 S-3 S-3 0001193125-25-065499 333-286168 25779289 33 336295
2025-03-12 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000950170-25-038262 005-91770 25733467 34 8340
2025-03-10 S-8 S-8 0001193125-25-050851 333-285677 25723585 33 99820
2025-03-10 10-K 10-K 0000950170-25-035929 001-39617 25722214 34 17752339 1 1
2025-03-10 8-K FORM 8-K 2.02,9.01 0001171843-25-001352 001-39617 25722194 34 288985 1 1
2025-03-04 4 xslF345X05/form4.xml 0001610717-25-000046 5328
2025-03-04 4 xslF345X05/form4.xml 0001610717-25-000045 5520
2025-03-04 4 xslF345X05/form4.xml 0001610717-25-000044 5509
2025-02-28 D xslFormDX01/primary_doc.xml 06b 0000950123-25-002925 021-539576 25690234 33 15712
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-001230 005-91770 25630416 34 10648
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-000862 005-91770 25612612 34 12469
2025-02-12 8-K 8-K 1.01,3.02,7.01,9.01 0001193125-25-024838 001-39617 25612197 34 1006779 1 1
2025-02-03 8-K 8-K 5.02 0001193125-25-019256 001-39617 25582445 34 151335 1 1
2024-11-18 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-11-18 16:00:00 9999999995-24-003508 333-283041 241473217 33 1780
2024-11-14 SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G 0001213900-24-098622 005-91770 241465113 34 88154
2024-11-14 SC 13G/A algs13ga3.htm 0000935836-24-000723 005-91770 241464949 34 48482
2024-11-14 SC 13G/A armistice-algs093024a1.htm 0001172661-24-005305 005-91770 241464040 34 90462
2024-11-14 SC 13G/A alyeska-algs093024a1.htm 0001172661-24-005266 005-91770 241463468 34 106168
2024-11-14 SC 13G/A ALIGOS THERAPEUTICS, INC. 0000902664-24-006624 005-91770 241463364 34 59362
2024-11-14 CORRESP filename1.htm 0001193125-24-258591 8261
2024-11-13 UPLOAD filename1.pdf 0000000000-24-012567 333-283041 40192
2024-11-12 SC 13G ALIGOS THERAPEUTICS, INC. 0000902664-24-006398 005-91770 241444193 34 75044
2024-11-06 S-8 S-8 0001193125-24-252201 333-283042 241432256 33 107115
2024-11-06 S-3 S-3 0001193125-24-252199 333-283041 241432201 33 767921
2024-11-06 10-Q 10-Q 0000950170-24-122371 001-39617 241431420 34 15432761 1 1
2024-11-06 8-K FORM 8-K 2.02,9.01 0001171843-24-006057 001-39617 241430868 34 274329 1 1
2024-10-10 4 xslF345X05/form4.xml 0001610717-24-000503 5367
2024-09-26 3 xslF345X02/form3.xml 0001610717-24-000495 13821
2024-09-12 SC 13G ALGS_SC13G.htm 0001783647-24-000001 005-91770 241295218 34 95920
2024-09-06 4 xslF345X05/form4.xml 0001610717-24-000466 5457
2024-09-06 4 xslF345X05/form4.xml 0001610717-24-000465 5332
2024-09-06 4 xslF345X05/form4.xml 0001610717-24-000464 5521
2024-09-05 8-K 8-K 8.01 0001193125-24-214188 001-39617 241281447 34 148602 1 1
2024-08-19 8-K 8-K 3.03,5.03,9.01 0001193125-24-202813 001-39617 241220452 34 177901 1 1
2024-08-09 4 xslF345X05/form4.xml 0001610717-24-000423 5311
2024-08-09 4 xslF345X05/form4.xml 0001610717-24-000422 5308
2024-08-09 3 xslF345X02/form3.xml 0001610717-24-000421 13773
2024-08-09 3 xslF345X02/form3.xml 0001610717-24-000419 13733
2024-08-08 8-K 8-K 5.02 0001193125-24-196966 001-39617 241188398 34 152059 1 1
2024-08-06 10-Q 10-Q 0000950170-24-091828 001-39617 241179425 34 8689850 1 1
2024-08-06 8-K FORM 8-K 2.02,9.01 0001171843-24-004482 001-39617 241179111 34 273583 1 1
2024-06-28 4 xslF345X05/form4.xml 0001610717-24-000372 5273
2024-06-28 4 xslF345X05/form4.xml 0001610717-24-000371 5310
2024-06-28 4 xslF345X05/form4.xml 0001610717-24-000370 5289
2024-06-28 4 xslF345X05/form4.xml 0001610717-24-000369 5310
2024-06-28 8-K 8-K 5.02,5.03,5.07,9.01 0001193125-24-172218 001-39617 241085434 34 197468 1 1
2024-05-31 8-K 8-K 3.01 0001193125-24-151729 001-39617 241009652 34 148650 1 1
2024-05-22 8-K 8-K 3.01,5.02 0001193125-24-144929 001-39617 24973193 34 151005 1 1
2024-05-15 8-K 8-K 5.02 0001193125-24-139476 001-39617 24952317 34 146881 1 1
2024-05-07 10-Q 10-Q 0000950170-24-054497 001-39617 24921997 34 7563312 1 1
2024-05-07 8-K FORM 8-K 2.02,9.01 0001171843-24-002612 001-39617 24921757 34 258543 1 1
2024-04-29 ARS ARS 0001193125-24-122248 001-39617 24890782 34 24724110
2024-04-29 DEFA14A DEFA14A 0001193125-24-122208 001-39617 24890562 34 736597
2024-04-29 DEF 14A DEF 14A 0001193125-24-122181 001-39617 24890431 34 1380166
2024-04-16 PRE 14A PRE 14A 0001193125-24-097951 001-39617 24848803 34 1379825
2024-03-12 S-8 S-8 0001193125-24-065970 333-277860 24742968 33 90600
2024-03-12 10-K 10-K 0000950170-24-029953 001-39617 24742261 34 12518237 1 1
2024-03-12 8-K FORM 8-K 2.02,9.01 0001171843-24-001294 001-39617 24742096 34 280168 1 1
2024-03-04 4 xslF345X05/form4.xml 0001610717-24-000124 5452
2024-03-04 4 xslF345X05/form4.xml 0001610717-24-000123 5454
2024-03-04 4 xslF345X05/form4.xml 0001610717-24-000122 5515
2024-03-04 4 xslF345X05/form4.xml 0001610717-24-000121 5329
2024-02-28 4 xslF345X05/form4.xml 0001610717-24-000102 7616
2024-02-28 4 xslF345X05/form4.xml 0001610717-24-000101 7632
2024-02-28 4 xslF345X05/form4.xml 0001610717-24-000100 17171
2024-02-28 4 xslF345X05/form4.xml 0001610717-24-000099 17173
2024-02-28 4 xslF345X05/form4.xml 0001610717-24-000098 17056
2024-02-28 4 xslF345X05/form4.xml 0001610717-24-000097 17237
2024-02-28 4 xslF345X05/form4.xml 0001610717-24-000096 7645
2024-02-28 4 xslF345X05/form4.xml 0001610717-24-000095 7653
2024-02-28 4 xslF345X05/form4.xml 0001610717-24-000094 7657
2024-02-28 8-K 8-K 5.02 0001193125-24-050987 001-39617 24697278 34 155701 1 1
2024-02-28 SC TO-I/A SC TO-I/A 0001193125-24-050959 005-91770 24697205 34 29277
2024-02-14 SC 13G/A algs13ga2.htm 0000935836-24-000204 005-91770 24640327 34 48519
2024-02-14 SC 13G/A ALIGOS THERAPEUTICS, INC. 0000902664-24-001727 005-91770 24639380 34 59264
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023723 005-91770 24638758 34 92412
2024-02-14 SC 13G/A AMENDMENT NO. 2 0001214659-24-002858 005-91770 24637380 34 85225
2024-02-14 SC 13G armistice-algs123123.htm 0001172661-24-001312 005-91770 24636762 34 90589
2024-02-14 SC 13G alyeska-algs123123.htm 0001172661-24-001196 005-91770 24635742 34 106733
2024-02-08 SC 13D/A SC 13D/A 0001193125-24-028548 005-91770 24610427 34 118037
2024-01-30 SC TO-I SC TO-I 0001193125-24-018712 005-91770 24575794 34 10856143
2024-01-25 SC TO-C SC TO-C 0001193125-24-014780 005-91770 24558487 34 28903
2024-01-25 8-K 8-K 8.01,9.01 0001193125-24-014769 001-39617 24558477 34 163682 1 1
2023-11-28 424B3 424B3 0001193125-23-284262 333-275636 231446284 33 209063
2023-11-27 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-11-27 16:00:00 9999999995-23-003451 333-275636 231441763 33 1731
2023-11-22 CORRESP filename1.htm 0001193125-23-282242 7642
2023-11-22 8-K 8-K 5.02 0001193125-23-282236 001-39617 231433418 34 147145 1 1
2023-11-21 UPLOAD filename1.pdf 0000000000-23-012755 40374
2023-11-17 S-3 S-3 0001193125-23-279833 333-275636 231419391 33 308654
2023-11-15 8-K 8-K 5.02 0001193125-23-277877 001-39617 231410491 34 141822 1 1
2023-11-07 SC 13G/A SC 13G/A 0001104659-23-115332 005-91770 231385100 34 64115
2023-11-07 3 OWNERSHIP DOCUMENT 0001104659-23-115329 7920
2023-11-07 D xslFormDX01/primary_doc.xml 06b 0001567619-23-007642 021-496669 231382513 33 15235
2023-11-06 SC 13D SC 13D 0001193125-23-271361 005-91770 231379961 34 54661
2023-11-02 10-Q 10-Q 0000950170-23-058256 001-39617 231372729 34 8594788 1 1
2023-11-02 SC 13G deeptrack-algs102323.htm 0001172661-23-003592 005-91770 231372295 34 105181
2023-11-02 8-K FORM 8-K 2.02,9.01 0001171843-23-006671 001-39617 231372179 34 273528 1 1
2023-10-27 4 xslF345X05/form4.xml 0001610717-23-000320 7475
2023-10-27 4 xslF345X05/form4.xml 0001610717-23-000319 9514
2023-10-27 4 xslF345X05/form4.xml 0001610717-23-000318 6218
2023-10-25 8-K 8-K 1.01,3.02,9.01 0001193125-23-263158 001-39617 231346676 34 617726 1 1
2023-10-18 8-K 8-K 8.01 0001193125-23-258115 001-39617 231331005 34 147903 1 1
2023-09-12 4 xslF345X05/form4.xml 0001610717-23-000277 5368
2023-09-12 4 xslF345X05/form4.xml 0001610717-23-000276 5411
2023-09-12 4 xslF345X05/form4.xml 0001610717-23-000275 5405
2023-09-12 4 xslF345X05/form4.xml 0001610717-23-000274 5431
2023-09-12 4 xslF345X05/form4.xml 0001610717-23-000273 5203
2023-09-07 8-K 8-K 3.01 0001193125-23-230611 001-39617 231242217 34 149558 1 1
2023-08-03 10-Q 10-Q 0000950170-23-038045 001-39617 231140397 34 9155603 1 1
2023-08-03 8-K FORM 8-K 2.02,9.01 0001171843-23-004975 001-39617 231139856 34 283101 1 1
2023-08-01 8-K 8-K 8.01 0001193125-23-200617 001-39617 231132502 34 149502 1 1
2023-07-25 8-K 8-K 5.07 0001193125-23-193424 001-39617 231108554 34 154961 1 1
2023-07-21 4 xslF345X05/form4.xml 0001610717-23-000217 5222
2023-07-21 4 xslF345X05/form4.xml 0001610717-23-000216 5214
2023-07-21 4 xslF345X05/form4.xml 0001610717-23-000213 5177
2023-07-21 4 xslF345X05/form4.xml 0001610717-23-000212 5201
2023-07-21 4 xslF345X05/form4.xml 0001610717-23-000210 5222
2023-06-02 DEFR14A DEFR14A 0001193125-23-159828 001-39617 23988677 34 12713
2023-05-04 10-Q 10-Q 0000950170-23-017890 001-39617 23889036 34 7998135 1 1
2023-05-04 8-K FORM 8-K 2.02,9.01 0001171843-23-002889 001-39617 23888609 34 261889 1 1
2023-04-28 ARS ARS 0001193125-23-127488 001-39617 23867849 34 13106670
2023-04-28 DEFA14A DEFA14A 0001193125-23-127438 001-39617 23867761 34 347891
2023-04-28 DEF 14A DEF 14A 0001193125-23-127382 001-39617 23867558 34 704154
2023-03-17 4 FORM 4 0001567619-23-005257 5664
2023-03-17 4 FORM 4 0001567619-23-005256 5730
2023-03-17 4 FORM 4 0001567619-23-005255 5722
2023-03-17 4 FORM 4 0001567619-23-005254 5690
2023-03-17 4 FORM 4 0001567619-23-005252 5656
2023-03-17 4 FORM 4 0001567619-23-005251 5504
2023-03-09 S-8 S-8 0001193125-23-066188 333-270417 23720329 33 86481
2023-03-09 10-K 10-K 0000950170-23-007033 001-39617 23719911 34 15094231 1 1
2023-03-09 8-K FORM 8-K 2.02,9.01 0001171843-23-001548 001-39617 23719717 34 280878 1 1
2023-02-14 SC 13G/A ALIGOS THERAPEUTICS, INC. 0000902664-23-001809 005-91770 23629231 34 60275
2023-02-14 SC 13G/A AMENDMENT NO. 1 0001214659-23-002389 005-91770 23628390 34 82947
2023-02-13 SC 13G/A algs13ga.htm 0000935836-23-000115 005-91770 23614872 34 47099
2023-02-09 SC 13G/A JHG PLC OWNS <5% 0001274173-23-000004 005-91770 23601916 34 10049
2023-02-08 SC 13G/A SC 13G/A 0001193125-23-028518 005-91770 23599866 34 37375
2022-12-27 SC 13G r1221221sc13g.htm 0001214659-22-015381 005-91770 221490982 34 91111
2022-12-27 UPLOAD filename1.pdf 0000000000-22-013927 39659
2022-12-22 CORRESP filename1.htm 0001193125-22-311384 65449
2022-12-08 UPLOAD filename1.pdf 0000000000-22-013221 47611
2022-11-02 10-Q 10-Q 0000950170-22-021248 001-39617 221354271 34 8914599 1 1
2022-11-02 8-K FORM 8-K 2.02,9.01 0001171843-22-007002 001-39617 221354004 34 280287 1 1
2022-08-04 10-Q 10-Q 0000950170-22-014815 001-39617 221137309 34 8552903 1 1
2022-08-04 8-K FORM 8-K 2.02,9.01 0001171843-22-005357 001-39617 221136501 34 286427 1 1
2022-07-11 4 FORM 4 0001567619-22-013870 5584
2022-07-11 4 FORM 4 0001567619-22-013869 5689
2022-07-11 4 FORM 4 0001567619-22-013868 5721
2022-07-11 4 FORM 4 0001567619-22-013867 5655
2022-07-11 4 FORM 4 0001567619-22-013866 5503
2022-07-11 4 FORM 4 0001567619-22-013865 5729
2022-06-27 4 FORM 4 0001567619-22-013392 5536
2022-06-27 4 FORM 4 0001567619-22-013391 5529
2022-06-27 4 FORM 4 0001567619-22-013390 5542
2022-06-27 4 FORM 4 0001567619-22-013389 5558
2022-06-27 4 FORM 4 0001567619-22-013388 5566
2022-06-27 4 FORM 4 0001567619-22-013387 5565
2022-06-27 8-K 8-K 5.07 0001193125-22-182802 001-39617 221044502 34 153160 1 1
2022-05-06 3 FORM 3 0001567619-22-009672 16694
2022-05-04 10-Q 10-Q 0000950170-22-007407 001-39617 22892006 34 7628414 1 1
2022-05-04 8-K FORM 8-K 2.02,9.01 0001171843-22-003216 001-39617 22891505 34 263756 1 1
2022-04-29 DEFA14A DEFA14A 0001193125-22-134018 001-39617 22876400 34 1107603
2022-04-29 DEF 14A DEF 14A 0001193125-22-129730 001-39617 22869852 34 709920
2022-03-30 8-K 8-K 8.01 0001193125-22-088448 001-39617 22783010 34 146174 1 1
2022-03-22 8-K 8-K 8.01 0001193125-22-081126 001-39617 22757233 34 150824 1 1
2022-03-10 S-8 S-8 0001193125-22-072061 333-263447 22729909 33 83320
2022-03-10 10-K 10-K 0000950170-22-003365 001-39617 22729198 34 23226555 1 1
2022-03-10 8-K FORM 8-K 2.02,9.01 0001171843-22-001773 001-39617 22729052 34 290307 1 1
2022-02-14 SC 13G aligostherapeutics13g.htm 0000935836-22-000180 005-91770 22634014 34 47056
2022-02-14 SC 13G/A aligos13ga1.htm 0000935836-22-000175 005-91770 22633031 34 59889
2022-02-14 SC 13G SCHEDULE 13G 0001104659-22-022802 005-91770 22632001 34 88070
2022-02-14 SC 13G/A ALIGOS THERAPEUTICS, INC. 0000902664-22-001723 005-91770 22631718 34 60310
2022-02-14 SC 13G JANUS HENDERSON GROUP PLC OWNS 5.7% OF ALIGOS CIK 0001799448 0001274173-22-000082 005-91770 22625509 34 10591
2022-02-10 SC 13G/A SC 13G/A 0001193125-22-034471 005-91770 22614227 34 42365
2022-02-10 SC 13G/A SC 13G/A 0001193125-22-034455 005-91770 22614110 34 39618
2022-02-10 SC 13G/A SEC SCHEDULE 13G 0000902219-22-000013 005-91770 22609601 34 33200
2022-02-08 4 FORM 4 0001567619-22-002893 8058
2022-02-08 4 FORM 4 0001567619-22-002892 7829
2022-02-08 4 FORM 4 0001567619-22-002891 8050
2022-02-08 4 FORM 4 0001567619-22-002890 8018
2022-02-08 4 FORM 4 0001567619-22-002889 7981
2022-02-04 SC 13G/A SEC SCHEDULE 13G 0001678858-22-000101 005-91770 22591222 34 37587
2022-02-04 SC 13G/A SEC SCHEDULE 13G 0001678858-22-000043 005-91770 22591131 34 18941
2022-01-31 SC 13D/A SC 13D/A 0001193125-22-023399 005-91770 22574353 34 62662
2022-01-06 8-K 8-K 8.01 0001193125-22-003165 001-39617 22513668 34 146405 1 1
2021-11-19 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-11-19 16:00:00 9999999995-21-004423 333-260774 211430044 33 1731
2021-11-18 4 FORM 4 0001567619-21-020770 5554
2021-11-18 3 FORM 3 0001567619-21-020768 11742
2021-11-18 8-K 8-K 5.02 0001193125-21-333831 001-39617 211424637 34 148099 1 1
2021-11-17 CORRESP filename1.htm 0001193125-21-332453 6992
2021-11-15 UPLOAD filename1.pdf 0000000000-21-013788 40244
2021-11-04 S-3 S-3 0001193125-21-320316 333-260774 211380906 33 1015537
2021-11-04 10-Q 10-Q 0001564590-21-054514 001-39617 211380400 34 9816856 1 1
2021-11-04 8-K FORM 8-K 2.02,9.01 0001171843-21-007561 001-39617 211379959 34 283020 1 1
2021-08-13 SC 13G aligos13g.htm 0000935836-21-000462 005-91770 211170903 34 60217
2021-08-05 10-Q 10-Q 0001564590-21-041653 001-39617 211148984 34 9754857 1 1
2021-08-05 8-K FORM 8-K 2.02,9.01 0001171843-21-005574 001-39617 211148130 34 77670
2021-07-01 424B4 424B4 0001193125-21-206345 333-257466 211066297 33 1396656
2021-06-30 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-06-30 16:30:00 9999999995-21-002615 333-257466 211063881 33 1731
2021-06-28 CORRESP filename1.htm 0001193125-21-202060 10489
2021-06-28 CORRESP filename1.htm 0001193125-21-202052 8447
2021-06-28 S-1 S-1 0001193125-21-201893 333-257466 211053290 33 1818019
2021-06-24 8-K 8-K 5.07 0001193125-21-198812 001-39617 211043669 34 20758
2021-06-24 8-K/A 8-K/A 5.02 0001193125-21-198804 001-39617 211043632 34 17704
2021-06-21 SC 13D/A SC 13D/A 0001193125-21-195170 005-91770 211031363 34 117734
2021-06-21 SC 13D/A SC 13D/A 0001193125-21-195127 005-91770 211031008 34 62133
2021-06-17 4 FORM 4 0001567619-21-012370 5551
2021-06-17 4 FORM 4 0001567619-21-012339 5529
2021-06-17 4 FORM 4 0001567619-21-012337 5522
2021-06-17 4 FORM 4 0001567619-21-012335 5559
2021-06-15 4 FORM 4 SUBMISSION 0000899243-21-023881 16961
2021-06-10 UPLOAD filename1.pdf 0000000000-21-007161 40434
2021-06-04 DRS filename1.htm 0000950123-21-007570 377-04970 21997233 33 1526272
2021-05-10 10-Q 10-Q 0001564590-21-026071 001-39617 21907529 34 7875972 1
2021-05-10 8-K FORM 8-K 2.02,9.01 0001171843-21-003344 001-39617 21907062 34 43814
2021-05-03 SC 13D/A SC 13D/A 0001193125-21-148141 005-91770 21884424 34 124942
2021-04-28 4 FORM 4 SUBMISSION 0000899243-21-017187 16960
2021-04-27 4 FORM 4 0001567619-21-008646 5530
2021-04-27 3 FORM 3 0001567619-21-008645 10949
2021-04-27 DEFA14A DEFA14A 0001193125-21-134270 001-39617 21859179 34 272504
2021-04-27 DEF 14A DEF 14A 0001193125-21-134253 001-39617 21859098 34 745325
2021-04-27 8-K 8-K 5.02 0001193125-21-134238 001-39617 21859053 34 17906
2021-03-23 S-8 S-8 0001193125-21-091296 333-254628 21765439 33 72929
2021-03-23 10-K 10-K 0001564590-21-014872 001-39617 21765071 34 16827828 1
2021-03-23 8-K FORM 8-K 2.02,9.01 0001171843-21-001999 001-39617 21764834 34 75928
2021-02-16 SC 13G ALIGOS THERAPEUTICS, INC. 0000902664-21-001431 005-91770 21639100 34 61567
2021-02-16 SC 13G SC 13G 0001104659-21-022721 005-91770 21632305 34 61716
2021-02-11 SC 13G SC 13G 0001193125-21-038482 005-91770 21619928 34 37544
2021-02-11 SC 13G SC 13G 0001193125-21-038470 005-91770 21619873 34 39833
2021-01-11 SC 13G SEC SCHEDULE 13G 0000902219-21-000003 005-91770 21519504 34 37635
2020-12-03 4 FORM 4 0001567619-20-020625 5658
2020-12-03 4 FORM 4 0001567619-20-020624 5828
2020-12-03 4 FORM 4 0001567619-20-020623 5618
2020-12-03 4 FORM 4 0001567619-20-020622 5581
2020-12-03 4 FORM 4 0001567619-20-020621 5429
2020-11-25 10-Q 10-Q 0001193125-20-303749 001-39617 201351989 34 6380784 1
2020-10-30 SC 13D SC 13D 0001193125-20-282616 005-91770 201277676 34 136188
2020-10-28 SC 13G SCHEDULE 13G 0001213900-20-033706 005-91770 201269039 34 49194
2020-10-22 SC 13D SC 13D 0001193125-20-274431 005-91770 201255220 34 107670
2020-10-22 4 FORM 4 SUBMISSION 0001209191-20-055572 13831
2020-10-22 4 FORM 4 SUBMISSION 0001209191-20-055562 11266
2020-10-22 SC 13G SEC SCHEDULE 13G 0001787092-20-000006 005-91770 201251998 34 19067
2020-10-20 4 FORM 4 0001567619-20-018012 25987
2020-10-20 4 FORM 4 0001567619-20-018010 33857
2020-10-20 4 FORM 4 0001567619-20-018008 26764
2020-10-20 4 FORM 4 0001567619-20-018006 13927
2020-10-20 4 FORM 4 0001567619-20-018004 15521
2020-10-20 4 FORM 4 0001567619-20-018003 15713
2020-10-20 4 FORM 4 0001567619-20-018001 42317
2020-10-20 4 FORM 4 0001567619-20-018000 42209
2020-10-20 S-8 S-8 0001193125-20-272903 333-249568 201248663 33 110298
2020-10-20 8-K 8-K 5.03,8.01,9.01 0001193125-20-272852 001-39617 201248316 34 239932
2020-10-19 424B4 424B4 0001193125-20-272151 333-249077 201246837 33 6688981
2020-10-15 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2020-10-15 16:30:00 9999999995-20-002863 333-249077 201242688 33 1731
2020-10-15 3 FORM 3 SUBMISSION 0001209191-20-054973 5806
2020-10-15 3 FORM 3 SUBMISSION 0001209191-20-054956 7033
2020-10-15 3 FORM 3 0001567619-20-017873 19257
2020-10-15 3 FORM 3 0001567619-20-017872 15323
2020-10-15 3 FORM 3 0001567619-20-017871 12900
2020-10-15 3 FORM 3 0001567619-20-017870 17695
2020-10-15 3 FORM 3 0001567619-20-017869 18230
2020-10-15 3 FORM 3 0001567619-20-017868 15710
2020-10-15 3 FORM 3 0001567619-20-017867 10596
2020-10-15 3 FORM 3 0001567619-20-017866 10539
2020-10-15 3 FORM 3 0001567619-20-017865 11383
2020-10-15 3 FORM 3 0001567619-20-017864 11432
2020-10-15 3 FORM 3 0001567619-20-017863 13539
2020-10-15 3 FORM 3 0001567619-20-017862 27992
2020-10-15 3 FORM 3 0001567619-20-017861 30602
2020-10-14 CERT 8A_Cert_ALGS.pdf 0001354457-20-000586 001-39617 201238537 34 202428
2020-10-13 CORRESP filename1.htm 0001193125-20-268627 14484
2020-10-13 CORRESP filename1.htm 0001193125-20-268617 8946
2020-10-13 8-A12B 8-A12B 0001193125-20-268246 001-39617 201235750 34 14211
2020-10-09 S-1/A AMENDMENT NO. 1 TO FORM S-1 0001193125-20-267346 333-249077 201234005 33 9128976
2020-10-05 SEC STAFF LETTER filename1.pdf 9999999997-20-004899 270828
2020-10-02 CORRESP filename1.htm 0001193125-20-262777 98927
2020-09-28 SEC STAFF LETTER filename1.pdf 9999999997-20-004802 276902
2020-09-25 CORRESP filename1.htm 0001193125-20-254770 46005
2020-09-25 S-1 S-1 0001193125-20-254760 333-249077 201201105 33 11002837
2020-09-23 UPLOAD filename1.pdf 0000000000-20-008935 52334
2020-08-26 DRS filename1.htm 0000950123-20-009341 377-03456 201134018 33 6018792
2020-01-16 D xslFormDX01/primary_doc.xml 06b 0001567619-20-001131 021-358226 20530066 33 16555

Latest XBRL company facts

One latest value per concept from companyfacts (251 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 42.61M 2021-08-04 2021 Q2 10-Q 2021-08-05 0001564590-21-041653
dei EntityPublicFloat Entity Public Float USD 19.90M 2025-06-30 2025 FY 10-K 2026-03-05 0001193125-26-092614
ffd NetFeeAmt NetFeeAmt USD 252.72 2026-08-04 S-8 2026-08-06 0001193125-26-337937
ffd TtlFeeAmt TtlFeeAmt USD 252.72 2026-08-04 S-8 2026-08-06 0001193125-26-337937
ffd TtlOfferingAmt TtlOfferingAmt USD 1.83M 2026-08-04 S-8 2026-08-06 0001193125-26-337937
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-08-04 S-8 2026-08-06 0001193125-26-337937
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 3.21M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 27.78M 2026-06-30 2026 Q2 10-Q 2026-08-06 0001193125-26-336851
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 491,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 15.15M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AccruedRoyaltiesCurrentAndNoncurrent Accrued Royalties USD 0 2022-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 13.56M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD 437,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 699.47M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition USD 108,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition USD 1.17M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 9.26M 2021-01-01 2021-09-30 2022 Q3 10-Q 2022-11-02 0000950170-22-021248
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 3.66M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs USD -875,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 3.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 6.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap Assets Assets USD 47.19M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AssetsCurrent Assets, Current USD 34.68M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 1,000 2021-09-30 2021 Q3 10-Q 2021-11-04 0001564590-21-054514
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 0 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 39.56M 2024-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-122371
us-gaap AvailableForSaleSecuritiesAndHeldToMaturitySecurities Available-for-sale Securities and Held-to-maturity Securities USD 23.14M 2020-12-31 2021 Q3 10-Q 2021-11-04 0001564590-21-054514
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One USD 39.56M 2024-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-122371
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 39.59M 2024-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-122371
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 0 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 15,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 31.09M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 54.90M 2026-03-31 2026 Q1 10-Q 2026-05-07 0001193125-26-212001
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 31.74M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD 13.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 134,112 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 115.80M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 6.25M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 6.25M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap CommonStockValue Common Stock, Value, Issued USD 9,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -46.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 7.89M 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 4.11M 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 5.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 238.52M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value USD 3.17M 2019-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 314,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 314,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 1,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap DebtInstrumentConvertibleBeneficialConversionFeature Debt Instrument, Convertible, Beneficial Conversion Feature USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 405,000 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-sale, Allowance for Credit Loss USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DebtSecuritiesAvailableForSaleAndHeldToMaturity Debt Securities, Available-for-sale and Held-to-maturity USD 19.03M 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Investment 0 2025-12-31 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap DeferredFinanceCostsNet Debt Issuance Costs, Net USD 442,000 2019-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 1.05M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 24,000 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 82.33M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 1.05M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsDomestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic USD 29.98M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsForeign Deferred Tax Assets, Operating Loss Carryforwards, Foreign USD 33,000 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 10.66M 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 806,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 4.66M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 1.70M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other USD 1.62M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 81.28M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 142,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 700,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay pure 0.018 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap Depreciation Depreciation USD 852,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap DerivativeGainLossOnDerivativeNet Derivative, Gain (Loss) on Derivative, Net USD -296,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap DerivativeLiabilitiesNoncurrent Derivative Liability, Noncurrent USD 461,000 2019-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap DividendsCommonStockCash Dividends, Common Stock, Cash USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -4.45 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -2.25 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -4.45 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.013 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.742 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.038 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.002 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.053 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent pure -0.003 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 5.99M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 3,000 2024-01-31 2024 Q3 10-Q 2024-11-06 0000950170-24-122371
us-gaap EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Share-based Payment Arrangement, Expense, Tax Benefit USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD -6.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap FinanceLeaseInterestExpense Finance Lease, Interest Expense USD 5,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap FinanceLeaseLiability Finance Lease, Liability USD 145,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap FinanceLeaseLiabilityCurrent Finance Lease, Liability, Current USD 59,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap FinanceLeaseLiabilityNoncurrent Finance Lease, Liability, Noncurrent USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap FinanceLeaseLiabilityPaymentsDue Finance Lease, Liability, Payment, Due USD 144,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Finance Lease, Liability, to be Paid, Year One USD 144,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap FinanceLeaseLiabilityPaymentsDueYearFive Finance Lease, Liability, to be Paid, Year Five USD 51,000 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap FinanceLeaseLiabilityPaymentsDueYearFour Finance Lease, Liability, to be Paid, Year Four USD 42,000 2022-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap FinanceLeaseLiabilityPaymentsDueYearThree Finance Lease, Liability, to be Paid, Year Three USD 44,000 2023-12-31 2023 FY 10-K 2024-03-12 0000950170-24-029953
us-gaap FinanceLeaseLiabilityPaymentsDueYearTwo Finance Lease, Liability, to be Paid, Year Two USD 42,000 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear Finance Lease, Liability, to be Paid, Remainder of Fiscal Year USD 19,000 2021-09-30 2021 Q3 10-Q 2021-11-04 0001564590-21-054514
us-gaap FinanceLeaseLiabilityUndiscountedExcessAmount Finance Lease, Liability, Undiscounted Excess Amount USD 20,000 2022-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap FinanceLeasePrincipalPayments Finance Lease, Principal Payments USD 86,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap FinanceLeaseRightOfUseAsset Finance Lease, Right-of-Use Asset, after Accumulated Amortization USD 296,000 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap FinanceLeaseRightOfUseAssetAccumulatedAmortization Finance Lease, Right-of-Use Asset, Accumulated Amortization USD 500,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization Finance Lease, Right-of-Use Asset, before Accumulated Amortization USD 700,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap FinanceLeaseWeightedAverageDiscountRatePercent Finance Lease, Weighted Average Discount Rate, Percent pure 0.056 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD 200,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD -17,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap GainLossOnSaleOfInvestments Gain (Loss) on Sale of Investments USD -57,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap GainOnSaleOfInvestments Gain on Sale of Investments USD 68,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 17.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap GovernmentAssistanceAmount GovernmentAssistanceAmount USD 11.30M 2025-04-01 2025-04-30 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap HeldToMaturitySecurities Debt Securities, Held-to-maturity USD 19.07M 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain USD 188,000 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss USD 0 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 3.92M 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One USD 3.92M 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap HeldToMaturitySecuritiesFairValue Debt Securities, Held-to-maturity, Fair Value USD 19.03M 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap ImpairmentOfInvestments Other than Temporary Impairment Losses, Investments USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-12 0000950170-24-029953
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -20.77M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -42.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD -3.11M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD -90.42M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-04 0001564590-21-054514
us-gaap IncomeTaxesPaid Income Taxes Paid USD 1,000 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 315,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 3.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 17.72M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncomeTaxReconciliationDeductionsOther Effective Income Tax Rate Reconciliation, Deduction, Other, Amount USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014872
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -5.01M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 896,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 1.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -768,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 27.78M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-06 0001193125-26-336851
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 1.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -569,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-122371
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap IncreaseDecreaseInOtherCurrentAssets Increase (Decrease) in Other Current Assets USD -2.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD -47,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap InterestIncomeExpenseNet Interest Income (Expense), Net USD 600,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 4,000 2020-01-01 2020-09-30 2021 Q3 10-Q 2021-11-04 0001564590-21-054514
us-gaap Investments Investments USD 0 2023-12-31 2023 FY 10-K 2024-03-12 0000950170-24-029953
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 5.42M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 1.11M 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 3.83M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 161,000 2023-12-31 2023 FY 10-K 2024-03-12 0000950170-24-029953
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 155,000 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 174,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 1.42M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 704,000 2021-09-30 2021 Q3 10-Q 2021-11-04 0001564590-21-054514
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 311,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap Liabilities Liabilities USD 35.88M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 47.19M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap LiabilitiesCurrent Liabilities, Current USD 19.60M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap LongTermInvestments Long-term Investments USD 15.11M 2021-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap LongTermPurchaseCommitmentAmount Long-term Purchase Commitment, Amount USD 4.50M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap LossContingencyAccrualAtCarryingValue Loss Contingency Accrual USD 0 2023-06-30 2023 Q2 10-Q 2023-08-03 0000950170-23-038045
us-gaap MinorityInterestChangeInRedemptionValue Noncontrolling Interest, Change in Redemption Value USD -11.39M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 150,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 59.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -46.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -46.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-06 0001193125-26-336851
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OperatingExpenses Operating Expenses USD 84.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -50.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OperatingLeaseCost Operating Lease, Cost USD 2.46M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 724,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 5.11M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 1.18M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 10.66M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OperatingLeasePayments Operating Lease, Payments USD 3.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 11.03M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 1.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.088 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 4.13M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OtherAssetsCurrent Other Assets, Current USD 2.94M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 268,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent USD 5,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -31,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -31,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 133,000 2022-09-30 2022 Q3 10-Q 2022-11-02 0000950170-22-021248
us-gaap OtherOperatingIncomeExpenseNet Other Operating Income (Expense), Net USD 1.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap PaymentOfFinancingAndStockIssuanceCosts Payment of Financing and Stock Issuance Costs USD 405,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 45.28M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap PaymentsToAcquireHeldToMaturitySecurities Payments to Acquire Held-to-maturity Securities USD 0 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap PaymentsToAcquireLongtermInvestments Payments to Acquire Long-term Investments USD 16.39M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 130,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap PaymentsToAcquireShortTermInvestments Payments to Acquire Short-term Investments USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 23,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 40.00M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 86.20M 2023-10-01 2023-10-31 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments Proceeds from Sale, Maturity and Collection of Short-term Investments USD 60.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 45.01M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-02 0000950170-23-058256
us-gaap ProceedsFromSaleOfHeldToMaturitySecurities Proceeds from Sale of Held-to-maturity Securities USD 10.00M 2021-01-01 2021-09-30 2022 Q3 10-Q 2022-11-02 0000950170-22-021248
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 23,000 2023-01-01 2023-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-122371
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 236,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 1.13M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 14.78M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 1.21M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap PurchaseObligation Purchase Obligation USD 4.10M 2021-09-30 2021 Q3 10-Q 2021-11-04 0001564590-21-054514
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 66.29M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap RestrictedCash Restricted Cash USD 110,000 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 645,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -688.61M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 5.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability USD 284,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 9.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 3.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 1.79M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 19.89M 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 12.86M 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 24.55M 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap SharePrice Share Price USD/shares 650 2020-09-30 2020 Q3 10-Q 2020-11-25 0001193125-20-303749
us-gaap ShortTermInvestments Short-term Investments USD 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 89,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 11.31M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.04 2024-08-19 2024 Q3 10-Q 2024-11-06 0000950170-24-122371
us-gaap StockIssuedDuringPeriodSharesReverseStockSplits Stock Issued During Period, Shares, Reverse Stock Splits shares 3.30M 2024-08-19 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 236,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 78.58M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 2,000 2025-07-01 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268203
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 23,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035929
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 100.69M 2019-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 10.00M 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 10.82M 2019-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 1.45M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 842,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003365
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 687,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 24.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 10.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 42.70M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0000950170-23-007033
us-gaap WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation shares 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092614
us-gaap WeightedAverageNumberOfSharesContingentlyIssuable Weighted Average Number of Shares, Contingently Issuable shares 0 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 10.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001193125-26-450798

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →